elb





Outline

Graphical abstract

- 2. SARS-CoV-2, COVID-19 and curcumin
- 3. Safety and limitations

CRediT authorship contribution statement

Declaration of competing interest

Acknowledgments

Show full outline 🗸

Figures (6)










European Journal of Pharmacology







Curcumin, a traditional spice component, can hold the promise against COVID-19?

Vivek Kumar Soni ^{a, 1}, Arundhati Mehta ^{a, 1}, Yashwant Kumar Ratre ^a, Atul Kumar Tiwari ^b, Ajay Amit ^c, Rajat Pratap Singh ^a, Subash Chandra Sonkar ^d, Navaneet Chaturvedi ^{c, f}, Dhananjay Shukla ^a 온 본, Naveen Kumar Vishvakarma ^a 온 본

Full length article

+ Add to Mendeley 🗠 Share 🥦 Cite

https://doi.org/10.1016/j.ejphar.2020.173551

Abstract

The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2). Curcumin, known for its pharmacological abilities especially as an anti-inflammatory agent, can be hypothesized as a potential candidate in the therapeutic regimen. COVID-19 has an assorted range of $pathophysiological\ consequences, including\ pulmonary\ damage,\ elevated$ inflammatory response, coagulopathy, and multi-organ damage. This review $% \left(1\right) =\left(1\right) \left(1\right) \left$ summarizes the several evidences for the pharmacological benefits of curcumin in COVID-19-associated clinical manifestations. Curcumin can be appraised to hinder cellular entry, replication of SARS-CoV-2, and to prevent and repair COVID-19associated damage of pneumocytes, renal cells, cardiomyocytes, hematopoietic stem cells, etc. The modulation and protective effect of curcumin on cytokine stormrelated disorders are also discussed. Collectively, this review provides grounds for its clinical evaluation in the therapeutic management of SARS-CoV-2 infection.

Graphical abstract



Previous article in issue

Keywords

COVID-19; Curcumin; Cytokine storm; Inflammation; Molecular targets

V.K. Soni and A. Mehta contributed equally to this work as first authors.

© 2020 Elsevier B.V. All rights reserved.

Part of special issue:

SI: Therapeutic targets and pharmacological treatment of COVID-19 Edited by George Booz



©PLUMX

> Download special issue

Recommended articles

Can selective serotonin reuptake inhibitors have... European Journal of Pharmacology, Volume 889, 2020...

Download PDF

Herbal immune-boosters: Substantial warriors .. Phytomedicine, 2020, Article 153361

Purchase PDF

Natural product derived phytochemicals in ma... Pharmacological Research, Volume 163, 2021, Article ...

Purchase PDF View details ∨

1 2 Next >

Citing articles (4) Article Metrics Citations Citation Indexes Social Media 83



Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookles** Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

